Q4 FY26 revenue stabilization after 3 quarters of decline
Expected: March 2026MEDIUM confidence
Q4 results due in March 2026 could show top-line inflection after consecutive quarterly declines
“Q3 FY26 revenue down 9.72% YoY and 5.41% QoQ”
Syncom Formulations (India) Ltd: Is It a Deep Value Opportunity?
AverageSteady Growth
As of Mar 28, 2026, Syncom Formulations (India) Ltd (Pharma - Others) has a deep value score of 53/100 (rated Average). Earnings are accelerating. 1Y return vs Nifty 500: -34%.
PE: Cycle BottomStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
💪Debt reduced 80% YoY — balance sheet strengthening
Re-Rating Catalysts
1. Q4 FY26 revenue stabilization after 3 quarters of decline
March 2026MEDIUM
2. Strategic partnership announcement
February-March 2026LOW
3. Asset monetization of land bank
Q2-Q3 FY27LOW
Value Trap Risks
1. Persistent revenue decline
HIGH2. Structural business challenges
HIGH3. Zero institutional interest
MEDIUMKey Numbers
PAT Growth YoY
+46%
Stable
Revenue YoY
-10%
Inflection Down
Operating Margin
18.0%
+600 bps YoY
PE Ratio
14.9
PEG Ratio
0.31
Current Price
₹11
3Y PAT CAGR
+35%
Market Cap
1.0K Cr
Valuation
Slightly UndervaluedIs Syncom Formulations (India) Ltd a Turnaround Opportunity?
Deep value thesis based on recent earnings • Updated Feb 22, 2026
Exceptional margin expansion (OPM up 687 bps YoY) and zero-debt strength overshadowed by temporary revenue contraction creates a classic deep value opportunity.
Verdict
EARLY_INNINGS
What Could Re-Rate Syncom Formulations (India) Ltd?
Re-rating catalysts over the next 2-4 quarters • Updated Feb 22, 2026
Strategic partnership announcement
Expected: February-March 2026LOW confidence
Board meeting scheduled for February 12, 2026 to review Q3 FY26 financial results may signal new initiatives
“Board meeting scheduled for February 12, 2026 to review Q3 FY26 results”
Asset monetization of land bank
Expected: Q2-Q3 FY27LOW confidence
Balance sheet shows ₹4.56B total assets vs ₹3.78B equity, indicating potential hidden value
“Total assets of ₹4.56B vs equity of ₹3.78B per Simply Wall St data”
What Are the Value Trap Risks for Syncom Formulations (India) Ltd?
Risks that could prevent re-rating or deepen the value trap
Persistent revenue decline
HIGHContinued revenue decline in Q4 FY26
Management view: Company has tightened credit terms to improve collections but hasn't addressed top-line growth drivers.
Monitor: Q4 FY26 revenue growth
Structural business challenges
HIGHNo improvement in long-term growth trajectory
Management view: Management has focused on cost optimization but hasn't articulated a clear growth strategy.
Monitor: 3-year revenue CAGR trend
Zero institutional interest
MEDIUMNo institutional accumulation in coming quarters
Management view: Management hasn't engaged with institutional investors to address concerns.
Monitor: Q4 FY26 institutional holding data
What Is Syncom Formulations (India) Ltd's Management Guidance?
Forward-looking targets from management for FY26
Management Tone: CAUTIOUS
Key Milestones
• Q4 FY26 revenue stabilization
• Potential strategic partnership announcement
How Fast Is Syncom Formulations (India) Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | -10% | +29% | Inflection Down |
| PAT (Net Profit) | +46% | +35% | Stable |
| OPM | 18.0% | +600 bps | Volatile |
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Other Deep Value Stocks in Pharma - Others
Frequently Asked Questions: Syncom Formulations (India) Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Syncom Formulations (India) Ltd's deep value score?
Syncom Formulations (India) Ltd has a deep value score of 53/100 (rated Average). This score is calculated from three components
- Earnings Score: 21/40 — measures PAT growth momentum across quarters
- Underperformance Score: 20/35 — how much the stock trails Nifty 500 (deeper underperformance = higher contrarian signal)
- Quality Score: 15/25 — operational quality (margins, revenue growth, valuation)
Is Syncom Formulations (India) Ltd fundamentally improving?
Syncom Formulations (India) Ltd's quarterly profit (PAT) growth trajectory
- Latest Quarter PAT Growth (QoQ): +14%
- Previous Quarter PAT Growth (QoQ): +5%
- 2 Quarters Ago PAT Growth (QoQ): -11%
- PAT Acceleration: +12.4pp (profits are accelerating)
- 2 consecutive quarters of positive PAT growth
Why is Syncom Formulations (India) Ltd underperforming despite good earnings?
Syncom Formulations (India) Ltd is underperforming the market despite improving earnings — this is the core deep value thesis
- 1-Year Return vs Nifty 500: -34%
- 6-Month Return vs Nifty 500: -27%
- 3-Month Return vs Nifty 500: -13%
- Yet average quarterly PAT growth is +3% — earnings are improving
- The market often takes time to re-rate stocks with improving fundamentals. This gap between price performance and earnings improvement is what deep value research seeks to identify.
What is the earnings momentum for Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd's earnings momentum is Steady — consistent growth.
- PAT QoQ progression: -11% → +5% → +14% (2Q ago → 1Q ago → latest)
- Acceleration: +12.4pp
- PAT YoY Growth: +46%
Is Syncom Formulations (India) Ltd undervalued?
Syncom Formulations (India) Ltd's valuation metrics
- Price-to-Earnings (PE): 14.0x
- Price-to-Book (PB): 2.7x
- PEG Ratio: 0.3x
- Margin of Safety: +19% (appears undervalued)
What are the revenue and margin trends for Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd's revenue and margin trends
- Latest Quarter Revenue Growth (QoQ): -5%
- Average Quarterly Revenue Growth: -8%
- Revenue Acceleration: +8.0pp
- Latest OPM Change: +3.3pp (margins expanding)
- Average OPM Change: +2.2pp
- Revenue YoY: -10%
What is Syncom Formulations (India) Ltd's trailing twelve month (TTM) performance?
Syncom Formulations (India) Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹70 Cr
- TTM PAT Growth: +79.5% YoY
- TTM Revenue: ₹503 Cr
- TTM Revenue Growth: +28.3% YoY
- TTM Operating Margin: 14.6%
What sector does Syncom Formulations (India) Ltd belong to?
Syncom Formulations (India) Ltd key facts
- Sector: Pharma - Others
- Market Cap: ₹1.0K Cr
- Rank in Pharma - Others: #2 by value score
- Overall rank among all deep value stocks: #58
Is Syncom Formulations (India) Ltd a good deep value opportunity to study?
Syncom Formulations (India) Ltd shows limited deep value signals currently — score is 53/100 (Average). Monitor for improvement.
- Value Score: 53/100 (Average)
- Earnings: Accelerating
- 1Y Underperformance: -34% vs Nifty 500
What is the bull and bear case for Syncom Formulations (India) Ltd?
Research Signals (Bull Case)
- Earnings accelerating — profit growth speeding up
- 2 consecutive quarters of positive PAT growth
- Appears undervalued based on fair value analysis
- Revenue growth also accelerating
- Operating margins expanding
Risk Factors (Bear Case)
- Significant underperformance (-34% vs Nifty 1Y)
Which other Pharma - Others stocks are deep value opportunities?
Other deep value stocks in Pharma - Others
- Unichem Laboratories Ltd — Score 57/100, Average, earnings accelerating
- Remus Pharmaceuticals Ltd — Score 53/100, Average, earnings accelerating
How does the Pharma - Others sector look for deep value?
Pharma - Others deep value sector overview
- 3 deep value stocks in this sector
- Average value score: 54/100
- Avg PAT acceleration: +108.5pp
- Top pick: Unichem Laboratories Ltd
What is deep value investing?
Deep value investing studies stocks that are underperforming the market despite showing improving fundamentals. The thesis is that the market has not yet recognized the earnings recovery, creating a potential valuation gap. It requires patience — recovery can take several quarters.
How is the deep value score calculated?
The deep value score (0-100) combines three factors:
- Earnings (0-40 pts): PAT growth across last 3 quarters, acceleration, and consecutive growth - Underperformance (0-35 pts): How much the stock trails Nifty 500 over 1Y, 6M, 3M (deeper underperformance = higher score) - Quality (0-25 pts): Revenue growth, margin trends, and valuation metrics (PEG, P/B)
Higher score indicates a stronger contrarian research signal.
What are the growth catalysts for Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd has 3 key growth catalysts identified from recent earnings analysis
- Q4 FY26 revenue stabilization after 3 quarters of decline
- Strategic partnership announcement
- Asset monetization of land bank
What are the key risks in Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd has 3 key risks worth monitoring
- Persistent revenue decline
- Structural business challenges
- Zero institutional interest
The above FAQs are generated from publicly available earnings data. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.